Vectura Group plc Director Declaration

Published: Apr 03, 2013

Chippenham, UK – 3 April 2013: In accordance with Listing Rule 9.6.14 (2) Vectura Group PLC (LSE:VEC) announces that John Brown, Senior Independent Non-Executive Director of Vectura, has been appointed as a Non-Executive Director of Electrical Geodesics, Inc. with effect from 3 April, 2013. Electrical Geodesics, Inc. was admitted to the AIM on 3 April, 2013.


Vectura Group plc +44 (0)1249 667700

Chris Blackwell, Chief Executive

Karl Keegan, Corporate Development Director

FTI Consulting +44 (0)20 7831 3113

John Dineen / Ben Atwell / Simon Conway

About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura’s main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura’s formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura’s business strategy. For further information, please visit Vectura’s website at

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Victoria Foster Mitchell

Senior Consultant

Strategic Communications

F T I Consulting

+44 (0)20 3077 0486 direct

+44 (0)7816 944 230 mobile

Holborn Gate, 26 Southampton Buildings

London, WC2A 1PB

Back to news